Valneva Shares Surge by 6.16%, Approaching a Key Resistance Level Ahead of Earnings
Valneva's stock price marked a significant increase of 6.16% this Tuesday during the session, reaching €4.97, in a Parisian market trending upwards with the CAC 40 gaining 2.16%. This rebound brings the weekly performance of the Nantes-based laboratory to over 7%, and its three-month gain to 31%. The stock is now nearing a critical technical threshold, just days before the announcement of its annual results.
Trading at €4.97, Valneva is now very close to its technical resistance located at €5.08. This level also coincides with the upper Bollinger band (€5.07), reinforcing its significance as a potential friction zone. A clear break through this threshold could pave the way for a new bullish phase, while a rejection would consolidate the hypothesis of a temporary cap. Moreover, the stock is trading well above its 50-day and 200-day moving averages, at €4.28 and €3.78 respectively, indicating a favorable underlying momentum over several months. On a yearly basis, the stock has risen by 48.68%. This movement comes six days before the group's annual 2025 results announcement, scheduled for March 16, which could be a potentially decisive catalyst for the stock's short-term trajectory.
Valneva's Rise in a Generally Favorable Market Session
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Valneva's increase is part of a generally favorable session in European markets. The CAC 40 is up 2.16% during the session, while the German DAX has gained 2.22% and the FTSE 100 has advanced by 1.67%. In Asia, the Nikkei 225 closed up 2.88% and the Hang Seng increased by 2.17%, providing a bullish relay to the Old Continent's exchanges. However, this improvement occurs in a context of increased volatility in global markets. The VIX, a volatility indicator for the S&P 500, was at 29.49 points in its last measurement on March 6, up sharply by 24.17% from the day before, indicating a high level of tension. Valneva's very low beta (0.01) however indicates that historically, the stock has almost no correlation with major indices, which moderates the direct impact of this ambient nervousness on its stock trajectory. The group's general assembly is scheduled for June 1, 2026.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
